Journal of Biosciences and Medicines
Vol.08 No.03(2020), Article ID:98831,10 pages
10.4236/jbm.2020.83013

Lignans from Morinda citrifolia (Noni) Fruit Inhibit Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase in Vitro

Brett J. West, Shixin Deng, Claude Jarakae Jensen

Research and Development, New Age Beverages., American Fork, Utah, USA

Copyright © 2020 by author(s) and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

Received: February 22, 2020; Accepted: March 10, 2020; Published: March 13, 2020

ABSTRACT

Morinda citrifolia (noni) fruit juice has exhibited a variety of biological activities in human clinical trials, indicating that it influences multiple systems of the body. Since the 1990s, the endocannabinoid system (ECS) has been found to modulate the activity of other organ systems. To investigate noni’s potential impact on the ECS, extracts from freeze-dried noni fruit were evaluated in fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibition assays. The ethyl acetate extract demonstrated the greatest activity against both enzymes. Lignans in this extract also inhibited enzyme activities, with americanin A being the most active in both assays. Americanoic acid and 3,3’-bisdemethylpinoresinol were the next most active compounds. These results suggest that lignans in noni fruit may influence endocannabinoid levels within the body via FAAH and MAGL inhibition. This reveals another set of probable mechanisms of action by which noni juice affects human health.

Keywords:

Morinda citrifolia, Noni, Endocannabinoid System, Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase

1. Introduction

Morinda citrifolia, commonly known as noni, is a small to medium sized tree that grows throughout the tropics. This tree produces fruit year-round, which has a history of use as both food and medicine [1]. Noni leaves, flowers, bark and roots were also used in folk medicine among Pacific Islanders as well as in Southeast Asia and the Caribbean [2]. In fact, noni was reportedly the most important and widely used Polynesian medicinal plant prior to the European era [3]. Various parts of the plant were thought to be useful for a broad range of health conditions [4] [5] [6]. This perception appears to be supported by the results of human clinicals trials, especially those involving noni fruit juice. Among the recorded effects of noni juice ingestion is control of inflammation, improved joint mobility, relief of discomfort, immune system modulation, protection against oxidative damage, maintenance of bone health, and improved mental health outcomes [7].

The wide array of noni juice health effects suggests that it interacts with multiple systems within the body, including the ECS. The ECS is involved in the regulation of the nervous, immune, digestive, reproductive, respiratory, renal, endocrine and cardiovascular systems [8] [9] [10] [11]. The ECS is composed principally of G protein-coupled receptors (GPCRs), lipid signaling molecules (endocannabinoids) and the enzymes responsible for endocannabinoid synthesis and catabolism. Among the GPCRs, the most prominent ECS receptors are cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2). But other GPCRs, or orphan receptors, that interact with endocannabinoids have also been discovered. There are two main endocannabinoids produced by the body, N-arachidonoylethanolamine (anandamide or AEA) and 2-arachidonoylglycerol (2-AG). AEA and 2-AG are synthesized from arachidonic acid derivatives, N-arachidonoyl phosphatidylethanolamine (NAPE) and diacylglycerol, by phospholipases and diacylglycerol lipases. AEA is eventually degraded by fatty acid amide hydrolase (FAAH) to arachidonic acid and ethanolamine. 2-AG is hydrolyzed by monoacylglycerol lipase (MAGL) and FAAH [12]. AEA and 2-AG are CB1 and CB2 ligands, and interactions between these produce physiological effects [13].

We previously reported that noni juice exhibits CB2 receptor agonist activity, indicating that some phytochemical constituents of noni fruit may exert an influence on the ECS via CB2 receptor binding [14]. We also discovered that processed noni fruit juice inhibits FAAH and MAGL in vitro [15]. Therefore, we sought to further investigate the interactions of various phytochemical constituents of noni fruit with FAAH and MAGL.

2. Materials and Methods

Noni fruit was harvested in French Polynesia and allowed to fully ripen. The fruit was then processed into a puree by mechanical removal of the seeds and skin, followed by pasteurization at a good manufacturing certified fruit processing facility in Mataiea, Tahiti. The puree was then freeze-dried. Twenty liters of methanol was percolated through 2 kg of the freeze-dried fruit puree powder. The methanol (MeOH) extract was concentrated via evaporation of the solvent. The MeOH extract was then diluted with 3 L water. Next, this was sequentially partitioned with 3 L petroleum ether (PetE) four times, 3 L ethyl acetate (EtOAc) three times, and 2 L butanol (BuOH) three times to yield corresponding extracts (Figure 1). The extracts were dried in vacuo with a rotary

Figure 1. Flow chart of the fractionation and isolation of noni fruit extracts and lignan compounds evaluated in FAAH and MAGL inhibition assays.

evaporator. The aqueous mother liquid was lyophilized to produce a dried water extract. Previously, the EtOAc extract was subjected to flash column chromatography, Sephadex LH-20, and reversed-phase preparative HPLC chromatography to yield several lignan compounds. Their chemical structures were elucidated by a series of spectroscopic techniques, including UV, IR, 1D and 2D NMR, as well as high resolution mass spectrometry. Several of these lignans displayed significant cyclooxygenase (COX) and lipoxygenase (LOX) inhibiting activity [16]. Other COX inhibitors have also been found to influence endocannabinoid catabolism [17]. Therefore, we focused on lignans from noni fruit in our assays, including morindolin, isoprincepin, 3,3’-bisdemethylpinoresinol, americanin A, americanoic acid A.

FAAH and MAGL inhibition assays were carried out as previously described, but with some modifications [18]. Human recombinant FAAH, human recombinant MAGL, 7-amino-4-methyl coumarin-arachidonamide (AMC-AA), and 4-nitrophenylacetate were obtained from Cayman Chemical Company (Ann Arbor, MI, USA). In the FAAH inhibition assay, the recombinant FAAH was diluted with Tris-HCl buffer (125 mM, pH 9.0) containing 1 mM EDTA. Noni fruit extracts were dissolved in DMSO with a final assay concentration of 500 μg/mL. Ten μL of each dissolved extract, or DMSO alone (vehicle control) were added to separate wells of a black plastic 96-well microplate. JZL195, was also included in the assay as a positive control. Inhibitor (samples and positive control) wells received 10 μL FAAH solution as well as additional 170 μL buffer. Background fluorescence wells, to which no FAAH was added, received 180 μL buffer. The microplate was incubated for five minutes at 37˚C. Ten μL of AMC-AA solution was then added to each well with a final concentration of 20 μM. The microplate was then incubated again at 37˚C for 30 minutes. Following incubation, the fluorescence intensity of each well was measured with a SynergyTM HT microplate reader (BioTek Instruments, Winooski, VT, USA) with 360 ± 40 nm excitation and 460 ± 40 nm emission. Fluorescence intensities (FI) were corrected by subtracting background well values from those of corresponding sample wells. Percent FAAH inhibition was calculated from the difference between the fluorescence intensities of the vehicle control (no inhibition) and the sample, divided by that of the vehicle control alone.

% FAAH inhibition = 100 × (FI control – FI sample)/FI control

In the MAGL assay, recombinant MAGL was diluted with Tris-HCl buffer (10 mM, pH 7.2) containing 1 mM EDTA. Extracts were dissolved in DMSO, and 10 μL of each solution was added to separate wells of a clear plastic 96-well microplate. Again, the final concentrated of each extract in the assay was 500 μg/mL. A positive control, JZL195, was also included in separate wells. Vehicle control (no extract or positive control) wells received only DMSO. Sample and positive control wells received 10 μL MAGL solution as well as additional 150 μL buffer. The background absorbance wells, with no MAGL, received 160 μL buffer. The wells were then incubated for 5 min. at room temperature. To each well, 10 μL of 4-nitrophenylacetate in ethanol (236 μM in final reaction solution) was added to begin enzymatic reactions. These were then incubated again at room temperature for 10 minutes. Afterwards, absorbance at 405 nm was then read with an ELX800 microplate reader (BioTek Instruments, Winooski, VT, USA). Absorbance values (A) were corrected by subtracting background well values from those of corresponding sample wells. Percent MAGL inhibition was calculated from the difference between control and sample absorbances divided by the absorbance of the control alone, as shown below.

% MAGL inhibition = 100 × (A control – A sample)/A control

Averages and standard deviations, expressed as mean ± standard deviation, were calculated for replicate analyses of the samples and positive control in both the FAAH and MAGL inhibition assays. These assays were conducted in 2019 at the research and development laboratory of New Age Beverages in American Fork, Utah.

3. Results and Discussion

All noni extracts inhibited FAAH activity to a greater degree than MAGL activity (Table 1). Against FAAH, the EtOAc, PetE and water extracts were the most active. But the EtOAc extract had the greatest potency, causing 85.5% ± 10.9% inhibition. This extract was also the most active extract in the MAGL assay. The PetE and the BuOH extracts modestly reduced MAGL function, but the MeOH and the water extracts were essentially inactive.

Since the EtOAC extract was the most effective against both enzymes, its phytochemical constituents were selected for further evaluation. We previously found that the EtOAc extract contains lignans that are biologically active against eicosanoid metabolizing enzymes. Therefore, we chose to assess the influence of five lignans in noni fruit on endocannabinoid hydrolysis enzymes.

Each lignan reduced both FAAH and MAGL activity (Table 2). However, three of the lignans had greater effects on MAGL. While all compounds reduced the

Table 1. Percent inhibition (mean ± standard deviation) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) by noni fruit extracts (500 μg/mL).

*JZL195 (positive control) tested at 50 nM, **JZL-195 tested at 4 μM.

Table 2. Percent inhibition (mean ± standard deviation) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) by lignans (200 μM) in noni fruit.

function of at least one enzyme by more than 50%, americanin A was the most potent. It inhibited MAGL and FAAH by 82.8 ± 4.2 and 78.3% ± 3.8%, respectively. The next most active lignans were americanoic acid and 3,3’-bisdemethylpinoresinol, with the former being slightly more active than the latter. It is interesting to note that while americanin A has a relatively equal effect on FAAH and MAGL, americanoic acid seems to be more selective against MAGL. Conversely, 3,3’-bisdemethylpinoresinol appears to be more selective against FAAH. While not as active as americanin A, isoprincepin also provides relatively balanced inhibition of both enzymes. Morindolin is more notable for its effect on FAAH.

Endocannabinoids accumulate at sites of injury and inflammation where they interact with cannabinoid receptors, transient receptor potential vanilloid 1 (TRPV1) ion channels and G protein-coupled GPR55 receptors to produce analgesia and anti-inflammatory effects [19] [20] [21]. Therefore, maintaining endocannabinoid tone, or levels, may produce analgesia. This possibility is demonstrated in the case of a 66-year-old female patient with lifelong history of pain insensitivity, rapid wound healing, and high stress tolerance [22]. The apparent cause was a single nucleotide polymorphism in FAAH that resulted in loss of enzyme function and elevated AEA signally. Additionally, URB597, a selective FAAH inhibitor, reduces neuropathic pain in Sprague-Dawley rats. But this analgesic effect is reduced when CB1 receptor and peroxisome proliferator-activated receptor alpha (PPAR alpha) antagonists are administered before URB597 [23]. MAGL inhibitors significantly reduce allodynia from chronic sciatic nerve constriction [24]. The dual FAAH/MAGL inhibitor JZL195 also reduces allydonia, motor incoordination, and catalepsy in C57BL/6 mice subjected to chronic constriction injury [25]. Interestingly, JZL195 reduced neuropathic pain better than selective FAAH or MAGL inhibitors alone. This suggests that substances which increase both AEA and 2-AG levels are more effective in treating pain at much lower doses, thus reducing the potential for side effects. The dual inhibition of these enzymes may also help explain the observed analgesic properties of noni juice in human patients [26].

ECS signaling is an important factor in regulating fear, anxiety, and other forms of psychological stress [27]. The amygdala processes emotions including fear and anxiety [28]. CB1 receptors are expressed at high levels in the amygdala, and decreased activation of these receptors appears to reduce expression of fear and anxiety in animal studies [29] [30]. Both FAAH deficient mice and those treated with an FAAH inhibitor had elevated brain AEA levels which lead to reduced anxiety when in the elevated plus maze [31]. In humans, a FAAH polymorphism resulting in ineffective enzyme activity is associated with lower general anxiety levels and enhanced fear extinction [32]. Further, 2-AG signalling appears to mitigate adverse effects of stress exposure, and the distruption of its synthesis impairs normal fear extinction in mice as well as increases anxiety-related behaviour [33] [34].

Noni juice improved the performance of male ICR mice, when compared to controls, in a Morris water maze (MWM) test following chronic restraint stress (CRS), as well as prevented stress-induced reduction in blood vessel density in the dentate gyrus of the hippocampus [35]. CRS increases FAAH activity and lowers AEA concentrations in the amygdala, increases anxiety and causes changes in amygdalar structure of C57/Bl6 mice. But none of these occur when FAAH deficient mice are subjected to CRS [36]. Further, the performance of MAGL knockout mice in hippocampus-dependent learning paradigms reveals that 2-AG signaling is important for learning and memory [3]. Therefore, FAAH and MAGL inhibition may be one of the mechanisms by which noni juice improved MWM performance.

We have found, for the first time, that lignans in noni fruit inhibit FAAH and MAGL activity. Only one lignan glycoside, pinoresinol 4-O-β-d-glucopyranoside, was previously reported to inhibit MAGL activity [37]. Rather, lignans are better known for their antioxidant, antitumor, anti-inflammatory, antiviral, antimicrobial, and neuroprotective activities [38]. In fact, the most active lignan in our assays, americanin A, exhibits antioxidant, antibacterial, and anti-tumor properties. It also inhibits melanin synthesis and matrix metalloproteinase-1 expression and enhances choline acetyltransferase activity [39] - [47]. We now know that lignans, especially those in noni fruit, may also influence endocannabinoid metabolism.

4. Conclusion

Our findings reveal that lignans represent a new class of FAAH and MAGL inhibitors. Further, noni fruit juice ingestion may prolong AEA and 2-AG interactions with CB1, CB2, and orphan G-protein receptors. As such, noni juice might be helpful in conditions associated with insufficient endocannabinoid tone. This possibility should be evaluated in vivo and in human clinical trials. Additional lignan compounds should also be evaluated for their abilities to interact with the ECS via FAAH and MAGL inhibition.

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

Cite this paper

West, B.J., Deng, S.X. and Jensen, C.J. (2020) Lignans from Morinda citrifolia (Noni) Fruit Inhibit Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase in Vitro. Journal of Biosciences and Medicines, 8, 143-152. https://doi.org/10.4236/jbm.2020.83013

References

  1. 1. West, B.J., Jensen, C.J., Westendorf, J. and White, L.D. (2006) A Safety Review of Noni Fruit Juice. Journal of Food Science, 71, R100-R106.https://doi.org/10.1111/j.1750-3841.2006.00164.x

  2. 2. Morton, J. (1992) The Ocean-Going Noni, or Indian Mulberry (Morinda citrifolia, Rubiaceae) and Some of Its “Colorful” Relatives. Economic Botany, 46, 241-256. https://doi.org/10.1007/BF02866623

  3. 3. Whistler, W.A. (1992) Polynesian Herbal Medicine. National Tropical Botanical Garden, Hong Kong.

  4. 4. Petard, P. (1986) Quelques Plantes Utiles de Polynesie Francaise et Raau Tahiti. Editions Haere Po No Tahiti, Papeete.

  5. 5. Brown, F.B.H. (1935) Flora of Southeastern Polynesia. III. Dicotyledons. Bishop Museum, Honolulu, HI.

  6. 6. Girardi, C., Butaud, J.F., Ollier, C., Ingert, N., Weniger, B., Raharivelomanana, P. and Moretti, C. (2015) Herbal Medicine in the Marquesas Islands. Journal of Ethnopharmacology, 161, 200-213. https://doi.org/10.1016/j.jep.2014.09.045

  7. 7. West, B.J., Deng, S., Isami, F., Uwaya, A. and Jensen, C.J. (2018) The Potential Health Benefits of Noni Juice: A Review of Human Intervention Studies. Foods, 7, 58. https://doi.org/10.3390/foods7040058

  8. 8. Pacher, P., Bátkai, S. and Kunos, G. (2006) The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58, 389-462. https://doi.org/10.1124/pr.58.3.2

  9. 9. Bab, I. and Zimmer, A. (2008) Cannabinoid Receptors and the Regulation of Bone Mass. British Journal of Pharmacology, 153, 182-188. https://doi.org/10.1038/sj.bjp.0707593

  10. 10. Borowska, M., Czarnywojtek, A., Sawicka-Gutaj, N., Woliński, K., Plazińska, M.T., Mikolajczak, P. and Ruchala, M. (2018) The Effects of Cannabinoids on the Endocrine System. Endokrynologia Polska, 69, 705-719. https://doi.org/10.5603/EP.a2018.0072

  11. 11. Eid, B.G. (2019) Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle. Journal of Microscopy and Ultrastructure, 6, 171-176.

  12. 12. Lu, H.C. and Mackie, K. (2016) An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry, 79, 516-525. https://doi.org/10.1016/j.biopsych.2015.07.028

  13. 13. Howlett, A.C. and Abood, M.E. (2017) CB1 and CB2 Receptor Pharmacology. Advances in Pharmacology, 80, 169-206. https://doi.org/10.1016/bs.apha.2017.03.007

  14. 14. Palu, A.K., Kim, A.H., West, B.J., Deng, S., Jensen, J. and White, L. (2008) The Effects of Morinda citrifolia L. (Noni) on the Immune System: Its Molecular Mechanisms of Action. Journal of Ethnopharmacology, 115, 502-506. https://doi.org/10.1016/j.jep.2007.10.023

  15. 15. West, B.J., Deng, S. and Jensen, C.J. (2019) Morinda citrifolia (Noni) Fruit Juice Inhibits Endocannabinoid Degradation Enzymes. Journal of Biosciences and Medicines, 7, 22-34. https://doi.org/10.4236/jbm.2019.77003

  16. 16. Deng, S., Palu, A.K., West, B.J., Su, C.X., Zhou, B.N. and Jensen, C.J. (2007) Lipoxygenase Inhibitory Constituents of the Fruits of Noni (Morinda citrifolia) Collected in Tahiti. Journal of Natural Products, 70, 859-862. https://doi.org/10.1021/np0605539

  17. 17. Scarpelli, R., Sasso, O. and Piomelli, D. (2016) A Double Whammy-Targeting Both Fatty Acid Amide Hydrolase (FAAH) and Cyclooxygenase (COX) to Treat Pain and Inflammation. ChemMedChem, 11, 1242-1251. https://doi.org/10.1002/cmdc.201500395

  18. 18. El-Alfy, A.T., Joseph, S., Brahmbhatt, A., Akati, S. and Abourashed, E.A. (2016) Indirect Modulation of the Endocannabinoid System by Specific Fractions of Nutmeg Total Extract. Pharmaceutical Biology, 54, 2933-2938. https://doi.org/10.1080/13880209.2016.1194864

  19. 19. Zygmunt, P.M., Ermund, A., Movahed, P., Andersson, D.A., Simonsen, C., Jonsson, B.A., Blomgren, A., Birnir, B., Bevan, S., Eschalier, A., Mallet, C., Gomis, A. and Hogestatt, E.D. (2013) Monoacylglycerols Activate TRPV1: A Link between Phospholipase C and TRPV1. PLoS ONE 8, e81618. https://doi.org/10.1371/journal.pone.0081618

  20. 20. Piomelli, D. and Sasso, O. (2014) Peripheral Gating of Pain Signals by Endogenous Analgesic Lipids. Nature Neuroscience, 17, 164-174. https://doi.org/10.1038/nn.3612

  21. 21. Sharir, H. and Abood, M.E. (2010) Pharmacological Characterization of GPR55, a Putative Cannabinoid Receptor. Pharmacology & Therapeutics, 126, 301-313. https://doi.org/10.1016/j.pharmthera.2010.02.004

  22. 22. Habib, A.M., Okorokov, A.L., Hill, M.N., Bras, J.T., Lee, M.C., Li, S., Gossage, S.J., van Drimmelen, M., Morena, M., Houlden, H., Ramirez, J.D., Bennett, D.L.H., Srivastava, D. and Cox, J.J. (2019) Microdeletion in a FAAH Pseudogene Identified in a Patient with High Anandamide Concentrations and Pain Insensitivity. British Journal of Anaesthesia, 123, e249-e253. https://doi.org/10.1016/j.bja.2019.02.019

  23. 23. Kim, M.J., Tanioka, M., Um, S.W., Hong, S.K. and Lee, B.H. (2018) Analgesic Effects of FAAH Inhibitor in the Insular Cortex of Nerve-Injured Rats. Molecular Pain, 14, 1-26. https://doi.org/10.1177/1744806918814345

  24. 24. Ignatowska-Jankowska, B., Wilkerson, J.L., Mustafa, M., Abdullah, R., Niphakis, M., Wiley, J.L., Cravatt, B.F. and Lichtman, A.H. (2015) Selective Monoacylglycerol Lipase Inhibitors: Antinociceptive versus Cannabimimetic Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics, 353, 424-432. https://doi.org/10.1124/jpet.114.222315

  25. 25. Adamson Barnes, N.S., Mitchell, V.A., Kazantzis, N.P. and Vaughan, C.W. (2016) Actions of the Dual FAAH/MAGL Inhibitor JZL195 in a Murine Neuropathic Pain Model. British Journal of Pharmacology, 173, 77-87. https://doi.org/10.1111/bph.13337

  26. 26. Wang, M.Y., Lutfiyya, M.N., Weidenbacher-Hoper, V., Peng, L., Lipsky, M.S. and Anderson, G. (2011) Morinda citrifolia L. (Noni) Improves the Quality of Life in Adults with Osteoarthritis. Functional Foods in Health & Disease, 1, 75-90.https://doi.org/10.31989/ffhd.v1i2.138

  27. 27. Lutz, B., Marsicano, G., Maldonado, R. and Hillard, C.J. (2015) The Endocannabinoid System in Guarding against Fear, Anxiety and Stress. Nature Reviews Neuroscience, 16, 705-718. https://doi.org/10.1038/nrn4036

  28. 28. Daviu, N., Bruchas, M.R., Moghaddam, B., Sandi, C. and Beyeler, A. (2019) Neurobiological Links between Stress and Anxiety. Neurobiology of Stress, 11, Article ID: 100191. https://doi.org/10.1016/j.ynstr.2019.100191

  29. 29. Katona, I., Rancz, E.A., Acsady, L., Ledent, C., Mackie, K., Hajos, N. and Freund, T.F. (2001) Distribution of CB1 Cannabinoid Receptors in the Amygdala and Their Role in the Control of GABAergic Transmission. Journal of Neuroscience, 21, 9506-9518. https://doi.org/10.1523/JNEUROSCI.21-23-09506.2001

  30. 30. Chhatwal, J.P. and Ressler, K.J. (2007) Modulation of Fear and Anxiety by the Endogenous Cannabinoid System. CNS Spectrums, 12, 211-220. https://doi.org/10.1017/S1092852900020939

  31. 31. Moreira, F.A., Kaiser, N., Monory, K. and Lutz, B. (2008) Reduced Anxiety-Like Behaviour Induced by Genetic and Pharmacological Inhibition of the Endocannabinoid-Degrading Enzyme Fatty Acid Amide Hydrolase (FAAH) Is Mediated by CB1 Receptors. Neuropharmacology, 54, 141-150. https://doi.org/10.1016/j.neuropharm.2007.07.005

  32. 32. Dincheva, I., Drysdale, A.T., Hartley, C.A., Johnson, D.C., Jing, D., King, E.C., Ra, S., Gray, J.M., Yang, R., DeGruccio, A.M., Huang, C., Cravatt, B.F., Glatt, C.E., Hill, M.N., Casey, B.J. and Lee, F.S. (2015) FAAH Genetic Variation Enhances Fronto-Amygdala Function in Mouse and Human. Nature Communications, 6, 6395. https://doi.org/10.1038/ncomms7395

  33. 33. Jenniches, I., Ternes, S., Albayram, O., Otte, D.M., Bach, K., Bindila, L., Michel, K., Lutz, B., Bilkei-Gorzo, A. and Zimmer, A. (2016) Anxiety, Stress, and Fear Response in Mice with Reduced Endocannabinoid Levels. Biological Psychiatry, 79, 858-868.https://doi.org/10.1016/j.biopsych.2015.03.033

  34. 34. Cavener, V.S., Gaulden, A., Pennipede, D., Jagasia, P., Uddin, J., Marnett, L.J. and Patel, S. (2018) Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice. Frontiers in Neuroscience, 12, 479. https://doi.org/10.3389/fnins.2018.00479

  35. 35. Muto, J., Hosung, L., Uwaya, A., Isami, F., Ohno, M. and Mikami, T. (2010) Morinda Citrifolia Fruit Reduces Stress-Induced Impairment of Cognitive Function Accompanied by Vasculature Improvement in Mice. Physiology and Behavior, 101, 211-217. https://doi.org/10.1016/j.physbeh.2010.04.014

  36. 36. Hill, M.N., Kumar, S.A., Filipski, S.B., Iverson, M., Stuhr, K.L., Keith, J.M., Cravatt, B.F., Hillard, C.J., Chattarji, S. and McEwen, B.S. (2013) Disruption of Fatty Acid Amide Hydrolase Activity Prevents the Effects of Chronic Stress on Anxiety and Amygdalar Microstructure. Molecular Psychiatry, 18, 1125-1135. https://doi.org/10.1038/mp.2012.90

  37. 37. Beladjila, K.A., Berrehal, D., De Tommasi, N., Granchi, C., Bononi, G., Braca, A. and De Leo, M. (2018) New Phenylethanoid Glycosides from Cistanche phelypaea and Their Activity as Inhibitors of Monoacylglycerol Lipase (MAGL). Planta Medica, 84, 710-715. https://doi.org/10.1055/s-0044-100187

  38. 38. Zalesak, F., Denis Bon, D.J. and Pospisil, J. (2019) Lignans and Neolignans: Plant Secondary Metabolites as a Reservoir of Biologically Active Substances. Pharmacological Research 146, Article ID: 104284. https://doi.org/10.1016/j.phrs.2019.104284

  39. 39. De La Cruz-Sánchez, N.G., Gómez-Rivera, A., Alvarez-Fitz, P., Ventura-Zapata, E., Pérez-García, M.D., Avilés-Flores, M., Gutiérrez-Román, A.S. and González-Cortazar, M. (2019) Antibacterial Activity of Morinda citrifolia Linneo Seeds against Methicillin-Resistant Staphylococcus spp. Microbial Pathogenesis, 128, 347-353. https://doi.org/10.1016/j.micpath.2019.01.030

  40. 40. Shin, Y., Jang, E.J., Park, H.J., Hong, J.Y., Kang, S.S. and Lee, S.K. (2016) Suppression of Melanin Synthesis by Americanin A in Melan: A Cells via Regulation of Microphthalmia-Associated Transcription Factor. Experimental Dermatology, 25, 646-647. https://doi.org/10.1111/exd.13013

  41. 41. Jung, C., Hong, J.Y., Bae, S.Y., Kang, S.S., Park, H.J. and Lee, S.K. (2015) Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2-p27 Axis in Human Colon Cancer Cells. Journal of Natural Products, 78, 2983-2993. https://doi.org/10.1021/acs.jnatprod.5b00743

  42. 42. Masuda, M., Murata, K., Naruto, S., Uwaya, A., Isami, F. and Matsuda, H. (2012) Matrix Metalloproteinase-1 Inhibitory Activities of Morinda citrifolia Seed Extract and Its Constituents in UVA-Irradiated Human Dermal Fibroblasts. Biological and Pharmaceutical Bulletin, 35, 210-215. https://doi.org/10.1248/bpb.35.210

  43. 43. Masuda, M., Itoh, K., Murata, K., Naruto, S., Uwaya, A., Isami, F. and Matsuda, H. (2012) Inhibitory Effects of Morinda citrifolia Extract and Its Constituents on Melanogenesis in Murine B16 Melanoma Cells. Biological and Pharmaceutical Bulletin, 35, 78-83. https://doi.org/10.1248/bpb.35.78

  44. 44. Masuda, M., Murata, K., Fukuhama, A., Naruto, S., Fujita, T., Uwaya, A., Isami, F. and Matsuda, H. (2009) Inhibitory Effects of Constituents of Morinda citrifolia Seeds on Elastase and Tyrosinase. Journal of Natural Medicines, 63, 267-273.https://doi.org/10.1007/s11418-009-0328-6

  45. 45. Su, B.N., Pawlus, A.D., Jung, H.A., Keller, W.J., McLaughlin, J.L. and Kinghorn, A.D. (2005) Chemical Constituents of the Fruits of Morinda citrifolia (Noni) and Their Antioxidant Activity. Journal of Natural Products, 68, 592-595. https://doi.org/10.1021/np0495985

  46. 46. Kamiya, Tanaka, Y., Endang, H., Umar, M. and Satake, T. (2004) Chemical Constituents of Morinda citrifolia Fruits Inhibit Copper-Induced Low-Density Lipoprotein Oxidation. Journal of Agricultural and Food Chemistry, 52, 5843-5848. https://doi.org/10.1021/jf040114k

  47. 47. Fukuyama, Y., Hasegawa, T., Toda, M., Kodama, M. and Okazaki, H. (1992) Structures of Americanol A and Isoamericanol A Having a Neurotrophic Property from the Seeds of Phytolacca americana. Chemical and Pharmaceutical Bulletin, 40, 252-254. https://doi.org/10.1248/cpb.40.252